Cyprus launches national awareness campaign for chronic kidney disease

A new national awareness campaign for chronic kidney disease (CKD) has been launched in Cyprus, supported by Alektor Pharmaceutical and AstraZeneca. The initiative operates under the auspices of the Cyprus Nephrology, Pathology, Diabetes, and Cardiology Societies. Experts highlight that CKD is a silent condition often progressing without symptoms until reaching advanced stages. Globally, the disease affects one in eight adults, with approximately 93 million people affected across Europe. In Cyprus, an estimated 80,000 individuals live with some form of CKD. Notably, 30% to 40% of patients remain undiagnosed due to the lack of early symptoms. The medical societies emphasize that early detection is possible through simple blood and urine tests. The campaign aims to encourage risk-group patients, including those with diabetes or hypertension, to undergo screening for timely intervention.